- cafead   Jul 08, 2024 at 11:52: AM
via Roche on Thursday announced that it will stop the Phase II/III SKYSCRAPER-06 study following disappointing data from its investigational anti-TIGIT antibody tiragolumab, which was unable to significantly improve survival in patients with non-small cell lung cancer.
article source
article source